CONVERSION FROM CALCINEURIN INHIBITOR-BASED TO EVEROLIMUS-BASED IMMUNOSUPPRESSION IN LIVER TRANSPLANT RECIPIENTS: LONG-TERM OUTCOME

被引：0
|
作者：
Dayangac, Murat [1 ]
机构：
[1] Istanbul Bilim Univ, Florence Nightingale Hosp, Istanbul, Turkey
来源：
TRANSPLANT INTERNATIONAL | 2017年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
EP042
引用
收藏
页码：363 / 363
页数：1
相关论文
共 50 条
  • [1] Everolimus-Based Immunosuppression in Liver Transplant Recipients
    Cholongitas, E.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (09) : 2488 - 2488
  • [2] CONVERSION TO EVEROLIMUS-BASED IMMUNOSUPPRESSION IN MAINTENANCE LIVER TRANSPLANT RECIPIENTS.
    Vallin, Melanie
    Guillaud, Olivier
    Morard, Isabelle
    Gagnieu, Marie Claude
    Mentha, Gilles
    Adham, Mustapha
    Morelon, Emmanuel
    Boillot, Olivier
    Giostra, Emiliano
    Dumortier, Jerome
    [J]. LIVER TRANSPLANTATION, 2009, 15 (07) : S245 - S246
  • [3] Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients
    Manzia, T. M.
    Angelico, R.
    Toti, L.
    Grimaldi, C.
    Sforza, D.
    Vella, I.
    Tariciotti, L.
    Lenci, I.
    Breshanaj, G.
    Baiocchi, L.
    Tisone, G.
    [J]. TRANSPLANTATION PROCEEDINGS, 2018, 50 (01) : 175 - 183
  • [4] Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients
    Vallin, Melanie
    Guillaud, Olivier
    Morard, Isabelle
    Gagnieu, Marie-Claude
    Mentha, Gilles
    Adham, Mustapha
    Morelon, Emmanuel
    Boillot, Olivier
    Giostra, Emiliano
    Dumortier, Jerome
    [J]. CLINICAL TRANSPLANTATION, 2011, 25 (04) : 660 - 669
  • [5] EVEROLIMUS-BASED IMMUNOSUPPRESSION TO REVERSE CALCINEURIN-INHIBITOR-ASSOCIATED MYOPATHIC SYMPTOMS IN HEART TRANSPLANT RECIPIENTS
    Meyer, S.
    Deuse, T.
    Baholli, L.
    Sattinger, E.
    Schlueter, M.
    von Stritzky, A.
    Reichenspurner, H.
    Costard-Jaeckle, A.
    [J]. TRANSPLANT INTERNATIONAL, 2011, 24 : 46 - 47
  • [6] Conversion to Everolimus-Based Immunosuppression Regimen with Calcineurin Inhibitor Reduction Ameliorates Histological Damage in Kidney Transplant Recipients with Calcineurin Inhibitor-Induced Nephrotoxicity.
    Hotta, K.
    Iwahara, N.
    Tanabe, T.
    Shinohara, N.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 1083 - 1083
  • [7] Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients
    Nogueras Lopez, Flor
    Abellan Alfocea, Patricia
    Ortega Suazo, Eva Julissa
    Lopez Garrido, Maria Angeles
    Becerra Massare, Antonio
    Gila Medina, Ana Maria
    Redondo Cerezo, Eduardo
    Espinosa Aguilar, M. Dolores
    [J]. TRANSPLANTATION PROCEEDINGS, 2020, 52 (02) : 556 - 558
  • [8] Long-Term Outcome after Early Mammalian Target of Rapamycin Inhibitor-Based Immunosuppression in Kidney Transplant Recipients
    Liefeldt, Lutz
    Waiser, Johannes
    Bachmann, Friederike
    Budde, Klemens
    Friedersdorff, Frank
    Halleck, Fabian
    Lachmann, Nils
    Peters, Robert
    Rudolph, Birgit
    Uenlue, Sinem
    Wu, Kaiyin
    Glander, Petra
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (15)
  • [9] Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients
    Mulgaonkar, Shamkant
    Kaufman, Dixon B.
    [J]. CLINICAL TRANSPLANTATION, 2014, 28 (11) : 1209 - 1224
  • [10] Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience
    Cholongitas, Evangelos
    Goulis, Ioannis
    Theocharidou, Eleni
    Antoniadis, Nikolaos
    Fouzas, Ioannis
    Giakoustidis, Dimitrios
    Imvrios, George
    Giouleme, Olga
    Papanikolaou, Vasilios
    Akriviadis, Evangelos
    Vasiliadis, Themistoklis
    [J]. HEPATOLOGY INTERNATIONAL, 2014, 8 (01) : 137 - 145
12345